SEC Form 4 · accession 0001289340-15-000061
Stereotaxis, Inc. · STXS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fred A Middleton
Director
Period of report
Jun 15, 2015
Accepted (ET)
Jun 16, 2015 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001289340
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 15, 2015 | S | 26,064 | $1.57 | D | 1,107,189 | I | Sanderling Venture Partners VI Co-Investment Fund, L.P. |
| Common Stock | holding | — | — | — | 46,810 | D | ||
| Common Stock | holding | — | — | — | 40,673 | I | Sanderling Ventures Management VI | |
| Common Stock | holding | — | — | — | 6,358 | I | Sanderling VI Limited Partnership | |
| Common Stock | holding | — | — | — | 5,335 | I | Sanderling VI Beteiligungs GmbH & Co. KG | |
| Common Stock | holding | — | — | — | 1,500 | I | Sanderling Mgmt. LLC 401K Pension Profit Sharing Plan | |
| Common Stock | holding | — | — | — | 53,275 | I | Sanderling IV Biomedical Co-Investment Fund, L.P. | |
| Common Stock | holding | — | — | — | 11,097 | I | Sanderling V Beteiligungs GmbH & Co. KG | |
| Common Stock | holding | — | — | — | 39,716 | I | Sanderling V Biomedical Co-Investment Fund, L.P. | |
| Common Stock | holding | — | — | — | 11,956 | I | Sanderling V Limited Partnership | |
| Common Stock | holding | — | — | — | 67,790 | I | Sanderling Venture Partners V Co-Investment Fund, L.P. | |
| Common Stock | holding | — | — | — | 22,451 | I | Sanderling Venture Partners IV Co-Investment Fund | |
| Common Stock | holding | — | — | — | 82 | I | Sanderling Ventures Management V |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide Stereotaxis, Inc., any security holders of Stereotaxis, Inc., or the staff of the Securities and Exchange Commission, upon request, all information regarding the number of shares purchased at each separate price within the range set forth in this footnote.